Log in

UK-Nordic Oncology Diagnostics Conference Programme

Moderator:	Loïc Kubitza, Director, Pharmaceuticals & Life Sciences, Price Waterhouse Coopers

08.30	Registration
	SESSION 1
09.00	Welcome Nick Archer HMA, British Ambassador to Denmark

09.10	KEYNOTE: An introduction to Companion diagnostics and Personalised Medicine in Cancer Jan Trøst Jørgensen Director of Medical Affairs, CMC Contrast AB and External Lecturer, Faculty of Pharmaceutical Sciences, Univ. of Copenhagen

09.30	KEYNOTE: Moving towards personalised healthcare Loïc Kubitza, Director, Pharmaceuticals & Life Sciences, Price Waterhouse Coopers

09.50	COMPANY PRESENTATION FINLAND: From treatments to trials: Personalisation from day one Pekka Simula, CEO, Oncos Therapeutics

10.00	KEYNOTE: Diagnostics Solutions for Personalised Medicine Dr Stephen Little, VP Personalised Medicine, Qiagen Manchester Ltd

10:20	Networking Coffee Break
	SESSION 2
11:00	KEYNOTE: Partnering in the Development of Targeted Oncology Therapies Cecilia Schott, PharmD MBA, Business Development Director, Personalized Healthcare, AstraZeneca Pharmaceuticals LP

11.20	COMPANY PRESENTATION DENMARK:How does drug-companion diagnostics co-development add value to the development of oncology pharmaceuticals? Henrik Winther, Director of Immunohistology and Companion Diagnostics, Dako A/S

11.30	COMPANY PRESENTATION UK: Development and provision of companion diagnostic services to the pharmaceutical and healthcare industries Berwyn Clarke, Chief Scientific and Development Officer, Lab 21 Ltd

11.40	COMPANY PRESENTATION SWEDEN: Quantifying protein-protein interactions in native cells and tissue samples - a new opportunity for Companion Diagnostics Mats Gullberg, Chief Technology Officer, Olink Bioscience

11.50	Networking Lunch
12.00	One to One Pre Booked Partnering
	SESSION 3
14.00	KEYNOTE:Development of Targeted Oncology Therapies at the Institute of Cancer Research, UK Dr. Jonathan Beech, Business Development Manager, The Institute of Cancer Research

14.20	COMPANY PRESENTATION DENMARK: Locked Nucleic Acids: Enabling MicroRNA Cancer Diagnostics Søren Morgenthaler Echwald, Vice President Business Development, Exiqon A/S

14.30	Networking coffee break

15.00	KEYNOTE:The molecular basis of chemosensitivity to cytotoxic agents Professor Ian A Cree, Director, Translational Oncology Research Centre, Portsmouth Hospitals NHS Trust / University of Portsmouth

15.20	COMPANY PRESENTATION NORWAY:DiaGenic - Norway's most innovative company 2009 Eric Christensen, CEO, Diagenic ASA

15.30	COMPANY PRESENTATION UK:The development of multigene prognostic and predictive tests for cancer management Dr Austin Tanney, Scientific Liason officer, Almac Diagnostics

15.40	COMPANY PRESENTATION SWEDEN:Estrogen receptor B selective agonists: First in class therapy for treatment of intra-hepatic cholangiocarcinoma? Stefan Nilsson, PhD, Associate Professor, Senior Project Manager, Karo Bio AB
15.50	COMPANY PRESENTATION ICELAND:Nationwide approach to chemo-sensitivity testing Finnbogi Thormodsson, University of Iceland

16.00	Networking Reception

17.00	End

To find out more about the Conference, please contact the organisers by emailing Christina Bergstrand, or call +46 86713065